Dajun Yang

机构：Sun Yat-sen University, Ascepion Pharmaceuticals (China), Ascendis Pharma (Denmark), Sun Yat-sen University Cancer Center, Department of Health of Guangdong Province · ORCID：0000-0002-6027-3604

发表论文 389 篇 · 总被引 8538 次 · h-index 46

代表论文

• Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study (2025 · Med · 被引 6)
• How the innovative advertising language style for nutrition products affects consumers' purchase intentions (2025 · Frontiers in Nutrition · 被引 4)
• Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK and ROS1 non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial (2025 · EClinicalMedicine · 被引 2)
• A phase 1 trial of APG-1387, an IAP antagonist, with nab-paclitaxel and gemcitabine in patients with refractory metastatic pancreatic cancer (2025 · Cell Reports Medicine · 被引 1)
• BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib for EGFR -mutated advanced non-small-cell lung cancer: a phase 1b trial (2026 · Journal for ImmunoTherapy of Cancer)
• Discovery of anIndole-Based p53-Y220C Reactivatorwith In Vivo Antitumor Activity via Structure-GuidedDesign (2026 · Figshare)